NEW YORK – PierianDx will integrate the Pillar Biosciences PiVAT cancer bioinformatics pipeline into its core technology platform, the companies announced Wednesday. Under the new partnership, Pillar Bio, which has co-headquarters in Boston and Shanghai, will market PieranDx clinical genomic reports along with its own cancer profiling assays.